Pravastatin Sodium has a cholesterol lowering agent. It has shorter half-life and undergoes first-pass metabolism. Frequent dose is required in case of conventional dosage form. The purpose of the study is to formulate and evaluate microcapsules containing Pravastatin Sodium by complex with cholestyramine resins coated with Eudragit RLPO and Eudragit RSPO polymers for achieving control release. Complexation of drug on resin was carried out by batch method. Microencapsulation was carried out by nonaqueous solvent evaporation method. Pharmacokinetic studies were done by using rats. The intermediate stability studies were carried out on the most satisfactory formulations. FTIR, X-ray diffraction, and DSC spectra of drug, drug-resinates, and polymers revealed no chemical interaction. The % DEE and % yield were observed for formulations of f1 to f7 that were varied from 97.1 ± 0.8 to 98.9 ± 0.5% and 95.0 ± 3.25 to 98.8 ± 7.1%, respectively. Most satisfactory formulation, f6, showed drug release up to 72.6%. No changes in % DEE and % CDR were observed after stability studies. Microcapsules of f6 formulation achieved best performance regarding in vitro drug release and from pharmacokinetic evaluation mean residence time was found to be 6.3 h, thus indicated, Pravastatin Sodium microcapsules were released and absorbed slowly over a prolonged period of time.

No abstract

Objective: Polymer-drug conjugates have gained much attention largely to curcumin lower drug solubility and to enhance drug stability. Curcumin is widely known for its medicinal properties including its anticancer efficacy. One of the serious drawbacks of curcumin is its poor water solubility which leads to reduced bioavailability. Materials and methods: Curcumin-HA conjugate was assessed for anticancer activity in EAC induced mice. And haematological parameters, differential count, body weight changes and mean survival time was assessed. Results: The results showed Conjugate (HA-Cur) produced extremely significant as anticancer activity by change in haematological parameters, differential count, body weight changes and mean survival time. Conclusion: Conjugated curcumin also showed potential anticancer activity.

No abstract

Objective: Polymer-drug conjugates have gained much attention largely to circumvent lower drug solubility and to enhance drug stability. Curcumin is widely known for its medicinal properties including its anticancer efficacy. One of the serious drawbacks of curcumin is its poor water solubility which leads to reduced bioavailability. Materials and methods: Synthesized hyaluronic acid-curcumin (HA-Cur) conjugate. The drug conjugate was characterized using FT-IR technique. The conjugates, interestingly found to assembles as micelles in aqueous phase. The formationof micelles seems to improve the stability of the drug in physiological pH. We also assessed cytotoxicity of the conjugate usingMCF-7, HBL 100 and Hela cell line and quantified by MTT assay. The results showed Conjugate Results: (HA-Cur) produced extremely significant reduction in percentage cell viability in dose dependent inhibitory effect on growth of cell lines. Conjugated curcumin also showed cytotoxicity reflecting its potential in targeted Conclusion: drug delivery applications.